Skip to main content area
Home
About
Company Profile
Strategy
Management Team
Board of Directors
Products
PRF-110
Product Pipeline
Clinical Trials
Market
Investors & Media
Investors Information
Press Releases
Events & Presentations
Contact
Website Menu
Close Menu
Home
About
Company Profile
Strategy
Management Team
Board of Directors
Products
PRF-110
Product Pipeline
Clinical Trials
Market
Investors & Media
Investors Information
Press Releases
Events & Presentations
Contact
Press Releases
7 Jan. 2021
PainReform to Present at the H.C. Wainwright Bioconnect 2021 Conference
6 Jan. 2021
PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations
6 Jan. 2021
PainReform Announces Appointment of Lotus Clinical Research as CRO for Phase 3 Clinical Trial of PRF-110
3 Dec. 2020
PainReform Appoints Senior Pharmaceutical Executive and Finance Veteran Ilan Hadar as Chief Executive Officer
5 Nov. 2020
PainReform Welcomes Senior Pharmaceutical Executive and Venture Capitalist Augustine Lawlor to Board of Directors
19 Oct. 2020
PainReform Highlights Surgical Advantages of PRF-110
29 Sep. 2020
PainReform Commences Preparations for Pivotal Phase 3 Clinical Trials
10 Sep. 2020
PainReform Announces Closing of $20.0 Million Initial Public Offering
8 Sep. 2020
PainReform Announces Pricing of $20.0 Million Initial Public Offering
Close
Font Resize
A-
A+
Reset font size
Keyboard navigation
Contrast
Choose color
black
white
green
blue
red
orange
yellow
navi
Underline links
Highlight Links
Clear cookies
Images Greyscale
Invert Colors
Close
Accessibility by WAH
